The ASIA PACIFIC LANCET AND PEN NEEDLES market is significantly influenced by the growing diabetes epidemic in the region. With a substantial increase in the number of individuals diagnosed with diabetes, there is a corresponding surge in the demand for lancets and pen needles for blood glucose monitoring and insulin administration, driving market growth. The LANCET AND PEN NEEDLES market in Asia pacific is shaped by progress in technology. The continual innovation with respect to the design of both lancet and pen needles, which are related to finer sample gauges, painless injection mechanisms, and improved safety measures leads to positive patient experience and compliance with diabetes management protocols.
Though Asia Pacific on a continual basis experiences the developments in healthcare infrastructure, they are generally responsible for increased accessibility and utilization of diabetes management devices. The developments whereby, healthcare centers are being developed more often, especially in the global areas where economic growth is taking shape is also created a climate for uptake of lancets and pen needles into the clinical routine practice.
Injection therapies for diabetes treatment, with insulin pens being one of the most popular choices, determine the amount of needles that are needed for pens. Established by the growing popularity in injecting healthcare, the trend for congruent self- administering pen needles changes the dynamics in the market.
The emergence of patient driven healthcare and self-monitoring drives the demand for lancets and pen needles. The adoption of pen needles and lancets are increased in the Asia Pacific region due to the demand of convenient and user-friendly devices thus blood glucose monitoring and insulin administration.
Public health programs and government initiatives that focus on diabetes control stimulate market development. The establishment of programs for the prevention and control of diabetes drives the adoption of these lancets and pen needles through subisidjie s, awareness campaigns, and the programs themselves.
Healthcare spending alone is a vital factor affecting the LANCET AND PEN NEEDLES market, other factors are such as income revenue and insurance coverage. Economic stability and decided allocation of government budget on health care affects purchasing power of both purchasers and consumers.
However, cultural specification and population health consciousness is shaping up lancets and pen needles adoption. As health consciousness is growing, there is a trend that people are willing to spend money on devices which allow them to monitor their blood glucose and administer insulin more regularly because such cultural values dictate that they promote wellness.
There is a demographic shift towards an aging population in some Asia Pacific countries which contributes to the incidence of diabetes and the appetite for lancets and pen needles. The market for suitable products targeted for older adults is driven by the diabetes management devices necessary for the older adults.
Intense competition for key players in the LANCET AND PEN NEEDLES market in the Asia Pacific forces the brand differentiation. Market competitors try to gain advantage by creating unique and interesting properties, quality of manufactured products and establishing a brand loyalty.
The adoption of telehealth services and remote monitoring technologies in Asia Pacific influences the market. Remote monitoring capabilities in lancet and pen needle devices allow healthcare providers to track patient data and provide timely interventions, aligning with the growing trend of digital healthcare solutions.
Intended Audience
The Asia Pacific lancet and pen needles market is segmented on the basis of therapy, gauge, needle length, and end users.
On the basis of the therapy, the market is segmented into insulin, glucagon-like peptide-1 (GLP-1), growth hormones, and others.
On the basis of the gauge, the market is categorized into 17/18G, 21G, 23G, and others.
On the basis of the needle length, the market is segmented into 4mm, 8mm, 12mm, and others.
On the basis of the end users, the market is segmented into hospitals & clinics, medical institutions & research organizations, and others.
Some of the key players in the Asia Pacific lancet and pen needles market are:
February 2024: Eli Lilly hopes to launch its bestselling antidiabetic medication, specified as Mounjaro (tripeptide), which will be around early next year. Indian health regulatory bodies, including Mounjaro, are currently investigating this.
June 2023: Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), was granted marketing authorization for its Adalimumab injection in prefilled syringe (PFS). It is a biosimilar for high concentration adalimumab formulation for rheumatoid arthritis treatment.
During CPHI Japan 2023, SHL Medical introduced Molly modular platform autoinjectors with pre-installed Needle Isolation Technology (NIT).
September 2022: The Microsoft and Novo Nordisk partnership was announced in September 2022, merging computational services, cloud computing AI and knowledge thirst in drug development as well as Novo Nordisk’s data engineering services.
On September 2022, Novo Nordisk acquired Forma Therapeutics. That company is committed to changing lives of Sickle cell disease (SCD) patients among other rare blood diseases.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)